{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:13:30Z","timestamp":1790090010213,"version":"4.0.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>In this study, we assessed the clinical efficacy and safety of Danlou tablets in the treatment of stable angina pectoris (SAP) with intermingled phlegm and blood stasis (IPBS), to provide high-quality evidence-based medical evidence for the prevention and treatment of coronary heart disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this multicenter randomized controlled study, 304 patients diagnosed with stable angina pectoris with IPBS enrolled from 12 national traditional Chinese medicine (TCM) clinical research centers in China were randomly assigned to the treatment group and the control group at a ratio of 1:1. Each group was divided into four subgroups based on the results of TCM syndrome differentiation: IPBS, IPBS combined with qi deficiency, IPBS combined with qi stagnation, and IPBS combined with toxin accumulation. The control group was treated with routine Western medicine. In addition to routine Western medicine treatment, the treatment group (the IPBS group) was treated with Danlou tablets or Danlou tablets supplemented by interventional therapies based on the results of traditional Chinese medicine differentiation. The frequency of angina attacks per week was the main efficacy evaluation indicator and the secondary efficacy evaluation indicators included angina symptom score, Seattle Angina Questionnaire, an electrocardiogram (ECG) efficacy evaluation, a cardiac Doppler two-dimensional ultrasound, an electrocardiogram treadmill exercise test, blood lipids, blood glucose, a coagulation function test, hemorheology indicators, homocysteine, C-reactive protein (CRP) or high sensitivity-CRP, TCM syndromes (syndrome score, tongue, pulse), and long-term prognosis (endpoint outcome, cardiovascular events).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 300 cases in the full analysis set (FAS), 266 in the per-protocol set (PPS), and 300 in the safety set. Regarding the main efficacy indicator, after treatment, the reduction in the frequency of weekly angina attacks in the treatment group was significantly greater than that in the control group (<jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.05). The results of the FAS and PPS were consistent. Regarding the secondary efficacy evaluation indicators, the angina symptom, TCM syndrome, ECG evaluation, Seattle Angina Pectoris Questionnaire, and 36-item Health Status Survey Summary Form scores of the treatment group were significantly higher than the control group (<jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.05) and the homocysteine levels of the treatment group were significantly reduced (<jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.05). The results of the FAS and PPS were consistent. In the PPS, the triglyceride levels in the treatment group were significantly lower than those in the control group after treatment (<jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.05). The activated partial thromboplastin time in the treatment group decreased significantly (<jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.05). There was no statistically significant difference in the safety indicators and incidence of adverse reactions between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Treatment with Danlou tablets and the modified combination therapy based on Western medicine treatment could improve angina pectoris symptoms of patients with SAP and IPBS syndrome and its concurrent syndromes, and improve patients\u2019 quality of life. Furthermore, the treatment is safe, has a long-term prognosis, and is worth further promotion and application in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.chictr.org.cn\/showproj.html?proj=39724<\/jats:uri>, ChiCTR registry, ChiCTR1900023708.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1462730","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T05:31:50Z","timestamp":1730266310000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of Danlou tablets in the treatment of stable angina pectoris with intermingled phlegm and blood stasis syndrome in coronary heart disease: a multicenter randomized controlled study"],"prefix":"10.3389","volume":"11","author":[{"given":"Zeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghua","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongchai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"B1","first-page":"521","article-title":"The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Summary of China's cardiovascular health and disease report 2020","volume":"36","year":"2021","journal-title":"Chin J Circ"},{"key":"B2","first-page":"1","article-title":"The Expert Committee on Rational Drug Use of the National Health and Family Planning Commission. Guidelines for reasonable drug use in coronary heart disease (2nd edition).","volume":"10","year":"2018","journal-title":"Chin J Med Front (Electr Edit)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.13193\/j.issn.1673-7717.2022.04.035","article-title":"Clinical efficacy and impact on quality of life of Tongmai Jiangzhuo Granule assisted intervention in patients with recurrent angina pectoris after coronary artery revascularization surgery","volume":"40","author":"He","year":"2022","journal-title":"Chin J Tradit Chin Med Pharmacy"},{"key":"B4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/1759-7714.12270","article-title":"Traditional Chinese medicine and cancer: history, present situation, and development","volume":"6","author":"Liu","year":"2015","journal-title":"Thorac Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"958","DOI":"10.13288\/j.11-2166\/r.2011.11.013","article-title":"Analysis of literature on the characteristics of traditional Chinese medicine syndromes of coronary heart disease in the past 40 years","volume":"52","author":"Mao","year":"2011","journal-title":"J Tradit Chin Med"},{"key":"B6","first-page":"2109","article-title":"Evidence based optimization design and consideration of traditional Chinese medicine treatment plans for stable angina pectoris in coronary heart disease","volume":"20","author":"Li","year":"2018","journal-title":"Modernization Tradit Chin Med Materia Medica-World Sci Technol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.13288\/j.11-2166\/r.2019.21.015","article-title":"China Association of Chinese Medicine Cardiovascular Disease Branch. Traditional Chinese medicine diagnosis and treatment guidelines for stable angina pectoris of coronary heart disease","volume":"60","year":"2019","journal-title":"J Tradit Chin Med"},{"key":"B8","first-page":"1198","article-title":"Systematic evaluation of Danlou tablets in the treatment of stable angina pectoris with phlegm and blood stasis obstruction","volume":"15","author":"Lu","year":"2017","journal-title":"Chin J Integr Med Cardio Cerebrovasc Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.13935\/j.cnki.sjzx.240204","article-title":"Meta analysis of the efficacy and safety of Danlou tablets combined with Western medicine in the treatment of coronary heart disease","volume":"19","author":"Gao","year":"2024","journal-title":"World J Integr Med"},{"key":"B10","first-page":"811","article-title":"Study on the mechanism of Danlou tablet against the proliferation of aortic smooth muscle cells in atherosclerosis model mice","volume":"40","author":"Miao","year":"2020","journal-title":"Chin J Integr Tradit Western Med"},{"key":"B11","first-page":"269","article-title":"The regulatory effect of Dan Lou tablets on lipid deposition, autophagy, and lipid metabolism in ApoE\u2212\/\u2212 mouse liver","volume":"34","author":"Zhu","year":"2023","journal-title":"Shi Zhen Tradit Chin Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.25040\/lkv2014.01.058","article-title":"European society of cardiology guidelines on the management of stable coronary artery disease (2013)","author":"Fayura","year":"2014","journal-title":"Lviv Cinical Bulletin"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.jtcvs.2014.11.002","article-title":"2014 ACC\/AHA\/AATS\/PCNA\/SCAI\/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease","volume":"149","author":"Fihn","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.13288\/j.11-2166\/r.2017.23.009","article-title":"Clinical epidemiological investigation of modern Chinese medicine syndrome characteristics of coronary heart disease","volume":"58","author":"Bi","year":"2017","journal-title":"J Tradit Chin Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.13288\/j.11-2166\/r.2023.10.015","article-title":"A literature study on the evolution of traditional Chinese medicine syndrome characteristics of coronary heart disease from 1970 to 2021","volume":"64","author":"Huang","year":"2023","journal-title":"J Tradit Chin Med"},{"key":"B16","first-page":"203","article-title":"The effect of Danlou tablets on the quality of life of heart rehabilitation patients after percutaneous coronary intervention","volume":"18","author":"Zhang","year":"2020","journal-title":"Chin J Integr Med Cardio Cerebrovasc Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.15912\/j.cnki.gocm.2019.34.133","article-title":"Observation on the therapeutic effect of Danlou tablets on angina pectoris in elderly patients with coronary heart disease after interventional stent implantation","volume":"17","author":"Yang","year":"2019","journal-title":"Guide China Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.15887\/j.cnki.13-1389\/r.2019.15.002","article-title":"Clinical efficacy of Danlou tablets in the treatment of coronary microcirculation disorders in acute myocardial infarction after percutaneous coronary intervention","volume":"12","author":"Zheng","year":"2019","journal-title":"Chin J Clin Rational Drug Use"},{"key":"B19","first-page":"75","article-title":"The therapeutic effect of Danlou tablets on angina pectoris in coronary heart disease patients undergoing stent implantation","volume":"10","author":"Liu","year":"2019","journal-title":"China Health Stand Manage"},{"key":"B20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.13288\/j.11-2166\/r.2008.02.038","article-title":"Practical randomized controlled trials and their applications in the field of traditional Chinese medicine","volume":"2","author":"Fei","year":"2008","journal-title":"J Tradit Chin Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3346\/jkms.2015.30.9.1213","article-title":"Endothelial dysfunction: clinical implications in cardiovascular disease and therapeutic approaches","volume":"30","author":"Park","year":"2015","journal-title":"J Korean Med Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1161\/01.RES.0000204825.66410.0b","article-title":"Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease","volume":"98","author":"Mikael","year":"2006","journal-title":"Circ Res"},{"key":"B23","first-page":"103","article-title":"Hyperhomocysteinemia and atherosclerosis","volume":"57","author":"Yang","year":"2005","journal-title":"Sheng Li Xue Bao"},{"key":"B24","first-page":"115","article-title":"The correlation between serum homocysteine and coronary heart disease and its pathogenesis","volume":"7","author":"Chen","year":"2015","journal-title":"J North Pharmacy"},{"key":"B25","first-page":"1112","article-title":"A study on the correlation between homocysteine levels and the occurrence and development of coronary heart disease","volume":"25","author":"Meng","year":"2021","journal-title":"Chin J Lab Diagnosis"},{"key":"B26","first-page":"65","article-title":"Clinical significance of plasma APTT, FIB, D-dimer, and hs CRP detection in patients with cerebral infarction","volume":"52","author":"Song","year":"2014","journal-title":"China Modern Doctor"},{"key":"B27","doi-asserted-by":"publisher","first-page":"15503","DOI":"10.16281\/j.cnki.jocml.2017.79.047","article-title":"Diagnostic value of activated partial thromboplastin time, fibrinogen, and apolipoprotein A1\/B ratio in coronary heart disease","volume":"4","author":"Fang","year":"2017","journal-title":"Electr J Clin Med Lit"},{"key":"B28","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/00045415-199911000-00012","article-title":"Hypertriglyceridemia and coronary heart disease risk","volume":"7","author":"Rosenson","year":"1999","journal-title":"Cardiol Rev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.jacc.2020.02.059","article-title":"Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and incident cardiovascular disease","volume":"75","author":"Duran","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B30","first-page":"659","article-title":"Research progress on the relationship between hypertriglyceridemia and coronary heart disease","volume":"13","author":"Huang","year":"2011","journal-title":"Chin J Geriatr Heart Brain Vessel Dis"},{"key":"B31","first-page":"1051","article-title":"Evaluation of the therapeutic effect of Danlou tablets on coronary heart disease angina pectoris with phlegm and blood stasis obstruction","volume":"32","author":"Wang","year":"2012","journal-title":"Chin J Integr Tradit Western Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/nejmra1510059","article-title":"Pragmatic trials","volume":"375","author":"Ford","year":"2016","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1038\/s41467-021-25667-4","article-title":"A randomized controlled trial of pharmacist-led therapeutic carbohydrate and energy restriction in type 2 diabetes","volume":"12","author":"Durrer","year":"2021","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/nejm200105243442106","article-title":"Is the placebo powerless?","volume":"344","author":"Hr\u00f3bjartsson","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1462730\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T13:01:23Z","timestamp":1730725283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1462730\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":34,"alternative-id":["10.3389\/fcvm.2024.1462730"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1462730","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"article-number":"1462730"}}